Pharmacogenetic and Antidepressant Treatment in Elderly
Not Applicable
Terminated
- Conditions
- Depression
- Registration Number
- NCT02856477
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Brief Summary
The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients.
Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
- current major depressive disorder
- antidepressant treatment
Exclusion Criteria
- dextromethorphan contra-indication
- other psychiatric disorder
- kidney failure
- liver failure mini mental State Examination (MMSE)<18
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method patient remission 6 months remission is defined by a Montgomery and asberg depression rating (MADRS) score\<10.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of cytochrome P450 2D6 in antidepressant metabolism for elderly patients with depression?
How does pharmacogenetic testing improve antidepressant efficacy in geriatric depression treatment?
What adverse events are associated with CYP2D6-guided antidepressant dosing in older adults?
Are there alternative drug classes for elderly depression that bypass CYP2D6 metabolism?
What biomarkers predict response to CYP2D6-adapted antidepressant therapy in geriatric populations?
Trial Locations
- Locations (1)
CHU Besancon
🇫🇷Besancon, Doubs, France
CHU Besancon🇫🇷Besancon, Doubs, France